Fasting Plasma Glucose and Hemoglobin A₁c in Identifying and Predicting Diabetes

The Strong Heart Study

Wenyu Wang, PhD
Elisa T. Lee, PhD
Barbara V. Howard, PhD
Richard R. Fabsitz, PhD
Richard B. Devereux, MD
Thomas K. Welty, MD, MPH

OBJECTIVE—To compare fasting plasma glucose (FPG) and HbA₁c in identifying and predicting type 2 diabetes in a population with high rates of diabetes.

RESEARCH DESIGN AND METHODS—Diabetes was defined as an FPG level ≥126 mg/dL or an HbA₁c level ≥6.5%. Data collected from the baseline and second exams (1989–1995) of the Strong Heart Study were used.

RESULTS—For cases of diabetes identified by FPG ≥126 mg/dL, using HbA₁c ≥6.5% at the initial and 4-year follow-up diabetes screenings (or in identifying incident cases in 4 years) among undiagnosed participants left 46% and 59% of cases of diabetes undetected, respectively, whereas for cases identified by HbA₁c ≥6.5%, using FPG ≥126 mg/dL left 11% and 59% unidentified, respectively. Age, waist circumference, urinary albumin-to-creatinine ratio, and baseline FPG and HbA₁c levels were common significant risk factors for incident diabetes defined by either FPG or HbA₁c, triglyceride levels were significant for diabetes defined by HbA₁c alone, and blood pressure and sibling history of diabetes were significant for diabetes defined by FPG alone. Using both the baseline FPG and HbA₁c in diabetes prediction identified more people at risk than using either measure alone.

CONCLUSIONS—Among undiagnosed participants, using HbA₁c alone in initial diabetes screening identifies fewer cases of diabetes than FPG, and using either FPG or HbA₁c alone cannot effectively identify diabetes in a 4-year periodic follow-up diabetes screening or incident cases of diabetes in 4 years. Using both criteria may identify more people at risk than the proposed models using the commonly available clinical measures can be applied to assessing the risk of incident diabetes using either criterion.

Diabetes Care 34:363–368, 2011

Type 2 diabetes has emerged as an important public health and economic problem in the U.S. More than 18 million Americans have diabetes and are at risk for related complications including heart disease, stroke, retinopathy, leg vessel disease, and kidney disease (1). Currently available therapeutic strategies in diabetes are only partially successful in preventing its complications. Therefore, diabetes screening in undiagnosed participants and early identification of those at high risk for intervention to prevent diabetes onset is very important for reducing diabetes-associated complications and medical care costs.

Criteria proposed for diagnosing incident diabetes by the American Diabetes Association (ADA) (2) based on fasting plasma glucose (FPG) have been used for a long time. Recently, an International Expert Committee (3) recommended a criterion based on HbA₁c. The cutoff point of an HbA₁c ≥6.5% suggested in their report was based on the association of HbA₁c with the prevalence of retinopathy from large cross-sectional studies (3). The ADA recently added HbA₁c as a diagnostic criterion of diabetes and suggested using either criterion (4). Therefore, it is important to know how these criteria perform in identifying prevalent diabetes in initial and successive diabetes screenings among undiagnosed participants and incident diabetic case subjects in a period of time and which risk factors predict incident diabetes defined by these criteria.

This report used longitudinal data from two exams (1989–1992 and 1993–1995) of the Strong Heart Study (SHS), a study to assess the prevalence and incidence of cardiovascular disease (CVD) and its risk factors in American Indians (5). This population has high rates of diabetes, and data from this population may be considered to be reflective of other populations who are at high risk for diabetes and diabetic CVD (6,7). This research compares the diagnosis of diabetes by HbA₁c or FPG and the risk factors for incident diabetes defined by the three criteria and develops prediction equations for incident diabetes using baseline HbA₁c, FPG, or both.

RESEARCH DESIGN AND METHODS—A total of 4,549 American Indian men and women, aged 45–74 years, in 13 Indian tribes/communities in Arizona, North/South Dakota, and Oklahoma, participated in the SHS baseline examination from 1989 to 1992 after providing written informed consent. The study was approved by all participating Indian tribes/communities and the Institutional Review Boards of the participating institutions and the Indian Health Service. The cohort was followed and...
reexamined in 1993–1995. The design and methods of the SHS have been previously reported in detail (5). Briefly, each examination included a personal interview and a physical examination. Blood was drawn at each examination after a 12-h fast, and total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglycerides (TGs), and FPG were measured. Diabetes status was defined by ADA 2004 criteria based on FPG (denoted as FPG-DM) (2) as diabetes if FPG ≥126 mg/dL or if on diabetes medications, as impaired fasting glucose (IFG) (or prediabetes) if 100 ≤ FPG < 126 mg/dL, and as normal fasting plasma glucose (NFG) if FPG <100 mg/dL; by International Expert Committee criteria based on HbA1c (denoted as A1C-DM) (3) as diabetes if HbA1c ≥6.5% or if on diabetes medications, prediabetes if 6.0 ≤ HbA1c < 6.5%, and nondiabetes otherwise; and by current ADA criteria based on both HbA1c and FPG (denoted as FPG/A1C-DM) (4) as diabetes if HbA1c ≥6.5% or FPG ≥126 mg/dL or if on diabetes medications and nondiabetes otherwise. A urine sample was taken to measure albumin and creatinine. Albuminuria was classified by urinary albumin-to-creatinine ratio (UACR) as microalbuminuria if 30 ≤ UACR < 300 mg/g and macroalbuminuria if UACR ≥ 300 mg/g. Obesity status was defined as obese if BMI ≥ 30 kg/m², overweight if 25 ≤ BMI < 30 kg/m², and normal if BMI < 25 kg/m². Three measurements of systolic blood pressure (SBP) and diastolic blood pressure (DBP) were taken on the right arm with an appropriately sized cuff using a Baum mercury sphygmomanometer (W.A. Baum Co., Copiague, NY) after the participant rested in a seated position for 5 min. The average of the second and third measurements was used as the blood pressure value for each participant. According to Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) criteria (8), hypertension (HTN) was defined as SBP/DBP ≥140/90 mmHg or on antihypertensive medications, normal if SBP <120 mmHg and DBP <80 mmHg, and prehypertension (Pre-HTN) otherwise. Leisure-time activities were measured at the baseline exam by the average exercise hours in the past week (AEHPW).

Metabolic syndrome traits described by the National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria (9) were also used in classification. Participants with SBP/DBP ≥130/85 mmHg or on treatment for hypertension were considered as having elevated blood pressure; waist circumference (WAIST) >102 cm in men or >88 cm in women was considered high (highWAIST); fasting TG ≥150 mg/dL was considered hypertriglyceridemia (hyperTG); and HDL-C <40 mg/dL in men or <50 mg/dL in women was considered low (lowHDL-C).

Data collected at the baseline and second exams from those participants who had HbA1c and FPG measured and did not receive insulin treatment or an oral agent for diabetes, were not on renal dialysis, and did not have a kidney transplant were used to compare the performances of HbA1c and FPG in identifying diabetes in undiagnosed participants. The risk factors data from the baseline exam and the incident diabetes status data from the second exam collected from participants without FPG-DM, A1C-DM, or FPG/A1C-DM at the baseline exam were used to explore significant predictors for cumulative incident FPG-DM, A1C-DM, and FPG/A1C-DM, respectively, and to compare effects of the baseline HbA1c or/and FPG in predicting the incident FPG/A1C-DM.

Statistical analyses

Frequency tables were used to explore the performances of HbA1c and FPG in identifying diabetes in undiagnosed participants. Logistic regression models (10) were used to compare risks of cumulative incident diabetes among subgroups of each risk factor after adjusting for age, sex, and center and to identify risk factors and build predictive models for cumulative incident FPG-DM, A1C-DM, and FPG/A1C-DM. Model-developing procedures were as follows: Step 1, candidate variables/risk factors for incident diabetes were selected among all potential categorical and continuous variables in the SHS data by a stepwise selection method with P = 0.05 for both entry and retention. These variables/risk factors included those reported in the literature (11–13) (i.e., age, sex, height, BMI, WAIST, SBP, DBP, current smoking status, hypertension status, parental or sibling history of diabetes, FPG, TC, LDL-C, HDL-C, TG, and the categorical metabolic syndrome traits) and additional variables (AEHPW, years of education, current alcohol intake, HbA1c, and UACR). Step 2, the final model was derived by adding those additional significant ones that were selected by the stepwise method again among the squares and interactions of those selected candidate continuous variables in the model selected at Step 1. Step 1 was for selecting an optimal subset of significant and independent risk factors of incident diabetes among all potential subsets of the candidate risk factors. Step 2 considered potential interaction and nonlinear relations of the selected candidate variables with incident diabetes. The ability of the predictive models to discriminate participants who will or will not develop diabetes was assessed by the area under the receiver operating characteristic curve (AROC) (14). An AROC value ≥0.70 indicates good discrimination ability. The performance of the proposed models was also assessed for calibration by comparing the number of observed and predicted diabetes events in 4 years using a Hosmer-Lemeshow statistic (15). A value of this statistic <20 is considered good calibration. The discrimination and calibration abilities of the derived predictive models were further internally validated by using internal bootstrap resampling (1,000 samples with the same size as the original cohort and with replacement) method described by Harrell et al. (16). The bootstrap-corrected AROC and P value of the Hosmer-Lemeshow statistic were used in assessing internal validation (16).

To compare performances of two different predictive models, we compared their AROCs (17). Statistical significance was defined as two-tailed P < 0.05 for all tests unless otherwise specified. SAS 9.1 was used for all analyses.

Results—The baseline characteristics from the SHS have been previously reported (6). Table 1 shows HbA1c by FPG classification based on data from the SHS participants who had HbA1c and FPG measured and did not receive diabetes medications, were not on renal dialysis, and did not have a kidney transplant at the baseline exam (n = 2,849) or at the second exam (n = 1,670) after excluding also all participants who had FPG/A1C-DM at the baseline exam). Therefore, the data from the baseline exam represent results of initial diabetes screening by using HbA1c or FPG in undiagnosed participants, whereas the data from the second exam, an average of 4 years after the initial screening, represent incident cases in participants without diabetes at baseline.

For prevalent cases of diabetes, based on the results from the baseline exam, HbA1c (≥6.5%) identified only 54%
Table 1—HbA1c, by FPG classification based on data from the baseline and second exams (1989–1995) of the SHS collected from American Indian participants who did not receive treatments for diabetes, were not on renal dialysis, and did not have a kidney transplant at the exams.

| HbA1c (%)  | Baseline exam FPG (mg/dL) | Second exam FPG (mg/dL) |
|-----------|--------------------------|-------------------------|
|           | (N = 2,849)              | (N = 1,670)*             |
|           | ≥126 | 100–125 | <100 | ≥126 | 100–125 | <100 |
| ≥6.5      | Frequency | 314 | 33 | 4 | 71 | 70 | 34 |
|           | Row percentage | 89.5 | 9.4 | 1.1 | 40.6 | 40.0 | 19.4 |
|           | Column percentage | 54.2 | 2.5 | 0.4 | 40.6 | 8.2 | 5.3 |
| 6.0–6.4   | Frequency | 73 | 92 | 29 | 19 | 66 | 38 |
|           | Row percentage | 37.6 | 47.4 | 15.0 | 15.5 | 53.7 | 30.9 |
|           | Column percentage | 12.6 | 7.0 | 3.0 | 10.9 | 7.7 | 5.9 |
| 4.75–5.9  | Frequency | 167 | 938 | 603 | 68 | 562 | 371 |
|           | Row percentage | 9.8 | 54.9 | 35.3 | 6.8 | 56.1 | 37.1 |
|           | Column percentage | 28.8 | 71.4 | 63.1 | 38.9 | 65.7 | 58.0 |
| <4.75     | Frequency | 25 | 251 | 320 | 17 | 157 | 197 |
|           | Row percentage | 4.2 | 42.1 | 53.7 | 4.6 | 42.3 | 53.1 |
|           | Column percentage | 4.3 | 19.1 | 33.5 | 9.7 | 18.4 | 30.8 |

*Those participants with FPG ≥126 mg/dL, HbA1c ≥6.5%, or on diabetes medications at the baseline exam were excluded. Row percentage 89.5 = 100 × 314/(314 + 33 + 4). Column percentage 54.2 = 100 × 314/(314 + 73 + 167 + 25).

[314/(314 + 73 + 167 + 25)] of those identified by FPG (≥126 mg/dL), whereas FPG identified 89% [314/(314 + 33 + 4)] of those diagnosed by HbA1c (Table 1). Using HbA1c alone identified only 57% [(314 + 33 + 4)/(314 + 73 + 167 + 25 + 33 + 4)] of all prevalent FPG/A1C-DM cases, whereas using FPG alone identified 94% [(314 + 73 + 167 + 25)/616]. For identifying cases of incident diabetes in 4 years, based on the results from the second exam, either HbA1c or FPG identified only 41% of those diagnosed by the other. Using either HbA1c or FPG alone identified 63% (175/279) of all incident FPG/A1C-DM cases. Because the data from the second exam also represent results from a 4-year periodic successive diabetes screening in participants without diabetes at baseline, this is also implied that for identifying cases of prevalent diabetes in a 4-year periodic successive diabetes screening in undiagnosed participants, using either FPG or HbA1c alone identified only 63% of all FPG/A1C-DM cases.

For cases of prevalent prediabetes in the baseline exam, among undiagnosed participants HbA1c (6–6.4%) identified 7% of those diagnosed by FPG (100–125 mg/dL), whereas FPG (100–125 mg/dL) identified 47% of those diagnosed by HbA1c (6–6.4%); in the second exam, HbA1c identified 8% of those diagnosed by FPG, and FPG diagnosed 54% of those diagnosed by HbA1c.

To examine how A1C-DM criterion from a single exam relate to the clinical requirement of a repeat value for diagnosis, we have evaluated those 277 undiagnosed baseline diabetic participants who had HbA1c ≥6.5% at the baseline exam and who also participated in the second exam. A total of 246 (88.8%) of the 277 undiagnosed participants received diabetes treatments (182) before the second exam or still had HbA1c ≥6.5% at the second exam; 258 (93.1%) of the 277 received diabetes treatments or had either HbA1c ≥6.5% or FPG ≥126 mg/dL at the second exam.

Table 2 compares the risks of developing incident A1C-DM, or FPG-DM, or FPG/A1C-DM in 4 years among subgroups of diabetes, indicating high reliability of discrimination and calibration. The respective figures were 0.76 and 0.5248 from the predictive model of incident FPG-DM and 0.70 and 0.3261 from the predictive model of incident FPG/A1C-DM, indicating good discrimination and calibration. The Hosmer-Lemeshow statistic of 0.74 and 0.2585, respectively, from the predictive model of incident FPG/A1C-DM, indicating good discrimination and calibration.
The risk-factor data from the baseline exam and the incident diabetes status data from the second exam collected from participants without A1C-DM, FPG-DM, or FPG/A1C-DM at the baseline exam were used to obtain the results for cumulative incident A1C-DM, FPG-DM, and FPG/A1C-DM, respectively. Albuminuria = normal, UACR < 30 mg/g; micro-, 30 ≤ UACR < 300 mg/g; and macro-, 300 mg/g ≤ UACR. FPG/A1C-DM = diabetes, FPG ≥ 126 mg/dL or on diabetes medications; IFG, 100 ≤ FPG < 126 mg/dL, and NFG, FPG < 100 mg/dL. FPG/A1C-DM = diabetes, FPG ≥ 126 mg/dL or on diabetes medications; IFG, 100 ≤ FPG < 126 mg/dL, and NFG, FPG < 100 mg/dL. FPG/A1C-DM = diabetes, HbA1c ≥ 6.5% or on diabetes medications; nondiabetic otherwise. Obesity = normal, BMI < 25 kg/m²; overweight, 25 ≤ BMI < 30 kg/m²; obese, BMI ≥ 30 kg/m². A1C-DM = diabetes, HbA1c ≥ 6.5% or on diabetes medications; nondiabetic otherwise. JNC-7 HTN status = normal, SBP < 140 mmHg and DBP < 90 mmHg; Pre-HTN, 120 ≤ SBP < 140 mmHg and DBP < 90 mmHg, or SBP < 140 and 80 ≤ DBP < 90 mmHg; HTN, SBP ≥ 140 or DBP ≥ 90 or on HTN medications. Metabolic syndrome traits = elevated blood pressure, SBP ≥ 130 mmHg, DBP ≥ 85 mmHg, or on HTN medications. HighWAIST = WAIST > 102 cm in men or > 88 cm in women. hyperTG = TGs ≥ 150 mg/dL. lowHDL-C = HDL-C < 40 mg/dL in men or < 50 mg/dL in women. Data in bold are significant.

predictive model of incident FPG/A1C-DM.

The predictive model for incident FPG/A1C-DM using both FPG and HbA1c at the baseline was significantly better than the predictive model for incident FPG/A1C-DM obtained by the same selecting procedures but without considering the baseline HbA1c (P = 0.0216), or the one without considering the baseline FPG (P = 0.0118) (data not shown). Risk calculators based on these proposed models are provided on the SHS Web site for general public, clinical physicians, or study investigators.

**CONCLUSIONS**—We found that using HbA1c alone in an initial diabetes screening among undiagnosed adults in a population-based sample identified fewer cases of prevalent diabetes than using FPG alone (Table 1). However, for identifying cases of prevalent diabetes in a 4-year periodic successive diabetes screening or identifying incident diabetes in 4 years in undiagnosed participants, each criterion missed cases of diabetes identified by the other (Table 1). We also showed that using both HbA1c and FPG identified a larger group of people at risk.

The discordances between diabetes identified by HbA1c and glucose criteria were also found in U.S. 2003–2006 National Health and Nutrition Examination Survey data (18) and in several other studies in different ethnic groups (19). In general, HbA1c, detected lower prevalence of diabetes than glucose criteria in U.S. and other populations, especially in undiagnosed participants (4,18,19), which is consistent with our findings in American Indians.

The discordances between diabetes identified by HbA1c and FPG among undiagnosed participants may be caused in part by the fact that HbA1c level reflects an integrated measure of glycemia over a 2- to 3-month period, whereas FPG reflects the influence of hepatic glucose output on the day of the visit (3,4,20).

We found that in the initial diabetes screening among undiagnosed participants at the baseline exam FPG ≥ 126 mg/dL identified more cases of diabetes than HbA1c ≥ 6.5%, but in a successive diabetes screening 4 years later, among undiagnosed participants the percentages were equal. The difference between the initial and successive diabetes screenings may be because at the baseline exam those newly diagnosed participants might have had unrecognized diabetes for many years, while those newly diagnosed at the successive exam might have had unrecognized diabetes for at most 4 years. This supports the contention that HbA1c ≥ 6.5% represents sustained daily hyperglycemia sufficient to meaningfully influence glycemia, whereas FPG ≥ 126 mg/dL may be a transient phenomenon that happens occasionally in many people. With a 4-year window, there is much less time to develop sustained hyperglycemia, and thus the two indicators are more comparable.

Since in the usual clinical situation there
has not been a screening in the near past, the discrepancy between HbA1c and FPG would likely prevail. The similar difference between the initial and successive diabetes screenings by using FPG and 2-h post plasma glucose was also reported in American Indians (21).

Our data show that a larger number of people at risk can be identified using both HbA1c and FPG. One cost-effective diabetes screening procedure could be to 1) measure HbA1c for all participants and 2) further measure FPG only for those participants with 4.75% \( \leq \) HbA1c < 6.5%, since our data show this would result in the identification of the most of remainder of those who would have diabetes by FPG criterion (Table 1). Others have also reported that using a method based on FPG and HbA1c in diabetes screening was more efficient (21).

The final set of variables in our model for predicting incident diabetes was selected among those reported variables in the literature (11–13) plus AEPHW, years of education, current alcohol intake, HbA1c, UACR, and additional interactions and nonlinear terms of these predictors. Each risk factor in the proposed models was associated significantly and independently to incident diabetes. Further studies are needed to see whether the risk-factor sets, independent contributions, and non-linearity still hold if data from other populations are used. Prediction models for diagnosis using either criterion were similar, with major baseline variables including glycemia, measured either by measure, obesity, WAIST, and UACR. Obesity and WAIST were important determinants; the latter, a reflection of abdominal fat, is closely associated with hyperinsulinemia and insulin resistance (22) and thus reflects the importance of insulin resistance as a determinant of type 2 diabetes. Glycemia, measured either by HbA1c or FPG, depending on the model, was also an important determinant; it has been shown in many analyses that diabetes risk increases as glycemia increases within the nondiabetic range. Albuminuria measured by UACR, a renal marker of CVD and inflammation, is also an important determinant in all models, which is consistent with our previous demonstrations that albuminuria is an important risk factor for diabetes, HTN, and CVD in American Indians (6,23,24). The associations of HbA1c, FPG, and Log(UACR) with incident diabetes were nonlinear, as evident by the quadratic forms of HbA1c, FPG, and Log(UACR) entered instead of the primary variables in the predictive models. For HbA1c this meant also that it changed directions from negative to positive association to incident diabetes at about HbA1c = 4.7%. The reason why HbA1c changed the direction of the association at about 4.7% was not clear and needs further study. Metabolic syndrome traits of elevated blood pressure and hyperTG also significantly predict incident diabetes in our models, similar to previous reports in the literature (12,25). This is likely because they also reflect insulin resistance.

The models for predicting incident A1C-DM, FPG-DM, or FPG/A1C-DM were all internally validated. The predictive model for incident FPG/A1C-DM using both FPG and HbA1c at the baseline was significantly better than the model without considering the baseline FPG or HbA1c.

This study has many strengths, including population-based sampling and systematic measures at two exams; further, this is a unique population that may become a reference for other populations with high rates of diabetes and diabetic CVD. Due to the high prevalence (~46%) of diabetes in American Indians, we are only able to use data collected from about half of 4,549 participants in the SHS cohort to derive predictive equations. Although our proposed models were internally validated, they should be tested and validated in other populations.
FPG/HbA1c in identifying and predicting diabetes

In conclusion, FPG and HbA1c criteria do not identify identical groups of individuals from a population-based sample as having diabetes. Using HbA1c alone to conduct an initial diabetes screening in undiagnosed participants detects fewer cases of prevalent diabetes than FPG alone. However, for identifying cases of prevalent diabetes in a 4-year periodic successive diabetes screening or identifying cases of incident diabetes in 4 years in undiagnosed participants, using either FPG or HbA1c alone was not effective. Baseline FPG or HbA1c levels, WAIST, and UACR were common significant and independent risk factors for incident diabetes defined by either FPG- or HbA1c-based criteria. Using both the baseline FPG and HbA1c to predict incident FPG/A1C-DM identified more people at risk. The proposed models can be applied to assess risk of incident A1C-DM, FPG-DM, or FPG/A1C-DM in American Indians and have potential applicability to other populations.

Acknowledgments—This study was supported by grants U01 HL-41642, U01 HL-41652, U01 HL-41654, and U01-HL65521 from the National Heart, Lung, and Blood Institute.

No potential conflicts of interest relevant to this article were reported.

W. W. performed all analyses and wrote the manuscript; E. T. L., B. V. H., R. R. F., R. B. D., and T. K. W. contributed to discussion and reviewed and edited the manuscript.

The authors express their appreciation to the 13 participating American Indian tribes/communities, the Indian Health Service, and the participants for their support and assistance.

The authors also thank SHS field center coordinators Beverly Blake and Alan Crawford (SD/ND), Betty Jarvis (AZ), and Dr. Taupeet Ali (OK) and the SHS staff for collecting the data.

References
1. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Bethesda, MD, U.S. Department of Health and Human Services, National Institute of Health, 2005
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29(Suppl. 1):S43–S48
3. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–1334
4. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl. 1):S11–S61
5. Lee ET, Welty TK, Fabrizi R, et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 1990;132:1141–1155
6. Lee ET, Welty TK, Cowan LD, et al. Incidence of diabetes in American Indians of three geographic areas: the Strong Heart Study. Diabetes Care 2002;25:49–54
7. Howard BV, Lee ET, Cowan LD, et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 1999;99:2389–2395
8. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–2572
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497
10. Lee ET, Wang JW. Statistical Methods for Survival Data Analysis. 3rd ed. New York, NY, John Wiley & Sons, Inc., 2003
11. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575–581
12. Schmidt MI, Duncan BB, Bang H, et al.; Atherosclerosis Risk in Communities Investigators. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005;28:2013–2018
13. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med 2007;167:1068–1074
14. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839–843
15. Hosmer DW, Lemeshow S. The Multiple Logistic Regression Model: Applied Logistic Regression. New York, NY, John Wiley & Sons Inc, 1989, p. 25–37
16. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–387
17. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845
18. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 2010;33:562–568
19. Christensen DL, Witte DR, Kaduka L, et al. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. Diabetes Care 2010;33:580–582
20. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 2006;55:1430–1435
21. Wang W, Lee ET, Fabrizi RR, Welty TK, Howard BV. Using HbA1c to improve efficacy of the American Diabetes Association fasting plasma glucose criterion in screening for new type 2 diabetes in American Indians: the Strong Heart Study. Diabetes Care 2002;25:1365–1370
22. Steinbaum SR. The metabolic syndrome: an emerging health epidemic in women. Prog Cardiovasc Dis 2004;46:321–336
23. Wang W, Lee ET, Fabrizi RR, et al. A longitudinal study of hypertension risk factors and their relation to cardiovascular disease: the Strong Heart Study. Hypertension 2006;47:403–409
24. Lee ET, Howard BV, Wang W, et al. Prediction of coronary heart disease in a population with high prevalence of diabetes and albuminuria: the Strong Heart Study. Circulation 2006;113:2897–2905
25. Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005;112:3066–3072